Home » Topics » BioWorld

BioWorld
RSS

DYNAGEN TO BEGIN PHASE II OF NICERASE

April 14, 1992

GOTTESMAN TAKES OVER GENOME PROJECT

April 14, 1992

BIOCHEM PHARMA OFFERING 3.5 MILLION SHARES

April 14, 1992

INVESTOR TO BUY TECHNICLONE SHARES

April 14, 1992

ROCHE LICENSES COMPOUNDS FROM XENOVA

April 14, 1992

CROP SELLS SHARES TO FUND INSECT VIRUS UNIT

April 13, 1992

APPOINTMENTS AND ADVANCEMENTS

April 13, 1992

CALYPTE PRIVATE PLACEMENT RAISES $6.3 MILLION

April 13, 1992

AMVAX AWARDED U.S. CONTRACT FOR VACCINE

April 13, 1992

VENTURE FUNDS RAISE $188 MILLION

April 13, 1992

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...